Serum BMP-2 Up-regulation as an Indicator of Poor Survival in Advanced Non-small Cell Lung Cancer Patients

Fei, Zhenghua; Yao, Chengyun; Yang, Xiaolei; Huang, Xin-En; Ma, Shenglin

doi:10.7314/apjcp.2013.14.9.5293

Cited by 45 publications

(43 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data are presented as means ± standard deviation (SD). We have enough experience in conducting medical researches, and have published some results elsewhere Dai et al, 2013;Deng et al, 2013;Gu et al, 2013;Fei et al, 2013;Shen et al, 2013;Sun et al, 2013;Wei et al, 2013;Yan et al, 2013;Gong et al, 2014;Zhang et al, 2014).…”

Section: Discussionmentioning

confidence: 99%

Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells

Ji¹,

Liu²,

Ju³

et al. 2014

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells

Ji¹,

Liu²,

Ju³

et al. 2014

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

“…Epidemiological surveys have confirmed that lung cancer is one cause of the most common cancer-related deaths all over the world (Fei, et al, 2013). The traditional therapies for lung cancer are mainly surgery, radiotherapy and chemotherapy.…”

Section: Figure 1 Mutation Sites In Egfr Exons 19 and 21 In Patientsmentioning

confidence: 99%

Analysis of CEA Expression and EGFR Mutation Status in Non-small Cell Lung Cancers

Yang¹,

Ding²,

Pen³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The serum carcinoembryonic antigen (CEA) level can reflect tumor growth, recurrence and metastasis. It has been reported that epidermal growth factor receptor (EGFR) mutations in exons 19 and 21may have an important relationship with tumor cell sensitivity to EGFR -TKI therapy. In this study, we investigated the clinical value of EGFR mutations and serum CEA in patients with non-small cell lung cancer (NSCLC). Materials and Methods:The presence of mutations in EGFR exons 19 and 21 in the tissue samples of 315 patients with NSCLC was detected with real-time fluorescent PCR technology, while the serum CEA level in cases who had not yet undergone surgery, radiotherapy, chemotherapy and targeted therapy were assessed by electrochemical luminescence. Results: The mutation rates in EGFR exons 19 and 21 were 23.2% and 14.9%, respectively, with the two combined in 3.81%. Measured prior to the start of surgery, radiotherapy, chemotherapy and targeted treatment, serum CEA levels were abnormally high in 54.3% of the patients. In those with a serum CEA level <5 ng/mL, the EGFR mutation rate was 18.8%, while with 5~19 ng/mL and ≥20 ng/mL, the rates were 36.4% and 62.5%. In addition, in the cohort of patients with the CEA level being 20~49 ng/mL, the EGFR mutation rate was 85.7%, while in those with the CEA level ≥50 ng/mL, the EGFR mutation rate was only 20.0%, approximately the same as in cases with the CEA level<5 ng/mL. Conclusions: There is a positive correlation between serum CEA expression level and EGFR mutation status in NSCLC patients, namely the EGFR mutation-positive rate increases as the serum CEA expression level rises within a certain range (≥20 ng/mL, especially 20~49 ng/mL). If patient samples are not suitable for EGFR mutation testing, or cannot be obtained at all, testing serum CEA levels might be a simple and easy screening method. Hence, for the NSCLC patients with high serum CEA level (≥20 ng/mL, especially 20~49 ng/mL), it is worthy of attempting EGFR-TKI treatment, which may achieve better clinical efficacy and quality of life.

show abstract

“…At present, the morbidity and mortality of lung cancer are the highest among malignant tumors all over the world, in which most of them result from infiltration and metastasis Fei et al, 2013;Cui et al, 2014;Hou et al, 2014). In recent years, relevant studies have revealed that cell adhesion molecules (CAMs) CD 44 v6 and E-cadherin (E-cad) are closely associated with infiltration and metastasis in a variety of tumors (Amirghofran et al, 2008;Wendt et al, 2011;Shiwu et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Correlation Between Expression of Cell Adhesion Molecules CD₄₄v6 and E-cadherin and Lymphatic Metastasis in Non-small Cell Lung Cancer

Li²,

Han³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Objective: To explore the relationship between expressions of cell adhesion molecules CD44 v6 and E-cadherin (E-cad) and lymphatic metastasis in non-small cell lung cancer (NSCLC). Materials and Methods: Eightyseven tissue samples obtained from patients with primary NSCLC were collected in our hospital from Dec., 2007 to Dec., 2012, and the expressions of CD44 v6 and E-cad gene proteins in these samples were detected by immunohistochemical method. Results: In the tissue without lymphatic metastasis, the positive expression rate of CD44 v6 was significantly lower, whereas the normal expression rate of E-cad was notably higher than that with lymphatic metastasis (55.6% vs. 78.4%, 47.2% vs. 21.6%), and both differences had statistical significance (P<0.05). Besides, CD44 v6 and E-cad expressions had a significant correlation in the NSCLC tissue with lymphatic metastasis (P<0.05). Conclusions: The positive expression of CD44 v6 and abnormal expression of E-cad may play a very important role in promoting lymphatic metastasis of NSCLC, with synergistic effect. Hence, detection of CD44 v6 and E-cad expressions is conductive to judging the lymphatic metastasis in NSCLC.

show abstract

Serum BMP-2 Up-regulation as an Indicator of Poor Survival in Advanced Non-small Cell Lung Cancer Patients

Cited by 45 publications

References 49 publications

Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells

Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells

Analysis of CEA Expression and EGFR Mutation Status in Non-small Cell Lung Cancers

Correlation Between Expression of Cell Adhesion Molecules CD₄₄v6 and E-cadherin and Lymphatic Metastasis in Non-small Cell Lung Cancer

Contact Info

Product

Resources

About

Serum BMP-2 Up-regulation as an Indicator of Poor Survival in Advanced Non-small Cell Lung Cancer Patients

Cited by 45 publications

References 49 publications

Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells

Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells

Analysis of CEA Expression and EGFR Mutation Status in Non-small Cell Lung Cancers

Correlation Between Expression of Cell Adhesion Molecules CD44v6 and E-cadherin and Lymphatic Metastasis in Non-small Cell Lung Cancer

Contact Info

Product

Resources

About

Correlation Between Expression of Cell Adhesion Molecules CD₄₄v6 and E-cadherin and Lymphatic Metastasis in Non-small Cell Lung Cancer